11 completed, 1 terminated, 1 unknown. 9 Phase 2, 3 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 8, Unknown 1 |
| Phase 3 | 3 | Completed 2, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
Follow Neothetics, Inc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat LIPO-202, Placebo for LIPO-202 - Submental Fat | Phase 2 | Completed | Neothetics, Inc | 162 | 2016-12-22 | 2017-10-20 |
| Safety and Efficacy Study of LIPO-202 for the Reduction of Central Abdominal Bulging in Obese Subjects LIPO-202, Placebo - Central Abdominal Bulging | Phase 2 | Completed | Neothetics, Inc | 120 | 2015-09-01 | 2015-12-24 |
| Extension Study to Evaluate the Post-Treatment Safety and Duration of Clinical Effect of LIPO-202 LIPO-202, Placebo - Central Abdominal Bulging | Phase 3 | Terminated | Evofem Inc. | 100 | 2015-06-01 | 2019-12-10 |
| Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2) LIPO-202, Placebo - Central Abdominal Bulging | Phase 3 | Completed | Evofem Inc. | 793 | 2015-04-09 | 2019-01-07 |
| Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat LIPO-202, Placebo - Central Abdominal Bulging | Phase 3 | Completed | Neothetics, Inc | 800 | 2015-04-01 | 2016-01-08 |
| An Open-Label Study to Evaluate Retreatment With LIPO-202 LIPO-202 - Central Abdominal Bulging | Phase 2 | Unknown | Neothetics, Inc | 150 | 2015-03-01 | 2015-08-13 |
| Dose Ranging Study Drug: salmeterol xinafoate, Drug: Placebo - Periumbilical Subcutaneous Adipose Tissue Reduction | Phase 2 | Completed | Neothetics, Inc | 472 | 2013-02-01 | 2015-03-26 |
| Dose-ranging Study salmeterol xinafoate, fluticasone propionate, Placebo, salmeterol xinafoate - Abdominal Contour Defects | Phase 2 | Completed | Neothetics, Inc | 200 | 2011-08-01 | 2015-03-26 |
| A Dose-ranging, Study of the Safety and Efficacy of Subcutaneous Injections of LIPO-102 Compared With Placebo for the Reduction of Abdominal Subcutaneous Adiposity LIPO-102, LIPO-102 Low, LIPO-102, Placebo - Weight | Phase 2 | Completed | Neothetics, Inc | 160 | 2010-04-01 | 2015-03-26 |
| An Evaluation of the Safety and Efficacy of LIPO-102 for the Reduction of Subcutaneous Abdominal Adiposity LIPO-102, Placebo - Subcutaneous Abdominal Adiposity | Phase 2 | Completed | Neothetics, Inc | 60 | 2009-10-01 | 2015-03-26 |
| Pilot Study to Determine Safety and Efficacy of Orbital Injections of LIPO-102 in Patients With Symptomatic Exophthalmos Associated With Thyroid-related Eye Disease (TED) LIPO-102, Placebo - Thyroid-Related Eye Disease | Phase 2 | Completed | Neothetics, Inc | 11 | 2009-09-01 | 2015-03-26 |
| Dose Ranging and Dose Frequency of LIPO-102 LIPO-102, Placebo - Subcutaneous Adipose Tissue Reduction | Phase 2 | Completed | Neothetics, Inc | 54 | 2009-06-01 | 2015-03-06 |
| An Evaluation of the Pharmacokinetics and Safety of LIPO-102 in Healthy Volunteers LIPO-102 - Subcutaneous Adipose Tissue Reduction | Phase 1 | Completed | Neothetics, Inc | 30 | 2009-02-01 | 2015-03-24 |
Body Weight (1) · Obesity (1)
Salmeterol Xinafoate (6) · Fluticasone-Salmeterol Drug Combination (1) · Injections (1)
United States (11) · Australia (1) · New Zealand (1)
Maria Feldman (5) · Daniel Piacquadio, MD (1) · Murray C Maytom, MBChB, MBA (1) · Murray Maytom (1)